Please verify your email address. Curious about the next Sticker Boom event date in Monopoly Go? Here is how you can predict when it might occur. Sticker Drop features eight milestones ...

TG Therapeutics' Q3 earnings missed EPS expectations, primarily due to higher non-cash compensation and increased R&D investments, despite Briumvi's revenue growth. Briumvi, a CD20-directed ...

U.S. net revenue from Briumvi grew by more than 230% year over year to $83.3 million. Total revenue for Q3 of $83.9 million surpassed analysts' expectations of $81.7 million. Diluted earnings per ...

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million at the mid-point. The results were slightly underwhelming but ...

The company has achieved significant market penetration with BRIUMVI, reaching nearly 1,100 prescribers across approximately 600 centers, including 95% of the top 100 MS centers. Positive long ...

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, with a key product, BRIUMVI, approved for treating relapsing forms of ...

The company reported strong Briumvi revenue in Q3, the analyst tells investors in a research note. The firm now has increased confidence in Briumvi’s growth prospects. TipRanks is the most ...

Under the terms of the manufacturing supply agreement, FUJIFILM Diosynth Biotechnologies will provide secondary US-based manufacturing supply for BRIUMVI at the Company’s new biopharmaceutical ...

Michael S. Weiss, the Company’s Chairman and Chief Executive Officer stated, “The positive feedback and uptake of BRIUMVI in the marketplace continues to outpace our expectations and we are excited to ...

A mesenchymal stem cell therapy led to significant improvements in quality-of-life scores for people with multiple sclerosis (MS) in a small clinical trial, according to the treatment’s ...